Next Science (ASX:NXS) said that former employee Michael Morello has filed a derivative complaint in Florida's Duval County Court, alleging breaches of fiduciary duties and mismanagement by several employees, according to a Wednesday filing with the Australian bourse.
Morello, who was Vice President of Wound Care Sales until December 2023, is also involved in a separate legal case initiated by the company in May 2024, alleging that he and other former employees breached post-employment restraints, the filing said.
Meanwhile, Morello's complaint claims Next Science's XBIO technology is not FDA-approved for biofilm eradication, and safety concerns about its Xperience surgical solution in breast implant procedures were not addressed, the filing added.
The company asserts that its products are FDA-approved, safe, and effective.
Next Science is conducting an independent investigation and will continue pursuing its non-compete action against Morello and former employees.
Shares of the company rose past 4% on market close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。